On April 2, 2026, President Trump signed an executive order imposing 100% tariffs on patented brand-name pharmaceutical products under Section 232 of the Trade Expansion Act. The tariffs take effect July 31, 2026 for large pharmaceutical companies and September 29, 2026 for smaller manufacturers. Generic drugs and orphan drugs are explicitly exempt, but many brand-name medications used by disability families are not protected.

The executive order targets imported patented pharmaceuticals as a national security and supply chain measure. While the administration exempted several categories, families who rely on brand-name neurological medications, ADHD treatments, and specialty formulations need to understand which of their medications may be affected and what steps they can take before the tariffs take effect.

What's Exempt and What's Not

The White House fact sheet lists several categories exempt from the 100% tariff:

• Generic drugs and their ingredients
• Orphan drugs (drugs designated under the Orphan Drug Act for rare diseases affecting fewer than 200,000 people)
• Nuclear medicines
• Plasma-derived therapies
• Fertility treatments
• Cell and gene therapies
• Antibody drug conjugates
• Medical countermeasures for chemical, biological, radiological, and nuclear threats

Drugs from the European Union, Japan, Korea, Switzerland, and Liechtenstein face a reduced 15% tariff. Companies that enter into "Most Favored Nation" pricing agreements with HHS and onshoring agreements with the Department of Commerce pay zero percent through January 20, 2029.

What's not exempt: patented brand-name medications that don't fall into the categories above. This includes many medications commonly prescribed for ADHD, epilepsy, anxiety, depression, and behavioral conditions when they're still under patent protection and don't qualify as orphan drugs.

What This Means for Families

The orphan drug exemption protects treatments for rare genetic conditions and ultra-rare neurological disorders. If your child takes a medication designated as an orphan drug, it's not affected by the tariff.

But orphan designation is narrow. A medication must be approved only for conditions affecting fewer than 200,000 people in the U.S. Many widely prescribed disability medications don't meet that threshold. Brand-name ADHD stimulants, anti-seizure medications used for common forms of epilepsy, and patented SSRIs prescribed for anxiety and depression are not orphan drugs.

The tariff applies to imported products. If a brand-name drug is manufactured domestically, it's not subject to the tariff. But according to reporting from STAT, a significant portion of brand-name medications and their active pharmaceutical ingredients are manufactured overseas, particularly in Europe and Asia.

Insurance coverage doesn't eliminate the impact. If the manufacturer faces a 100% tariff on an imported drug, that cost is passed to insurers, which can lead to higher premiums, increased prior authorization requirements, or drugs being dropped from formularies. Families on Medicaid may see medications moved to higher tiers or requiring additional documentation.

Which Disability Medications May Be Affected

You need to know three things about each medication your child takes: whether it's brand-name or generic, whether it's designated as an orphan drug under the Orphan Drug Act, and where it's manufactured. If it's imported and patented but not an orphan drug, it may be subject to the tariff.

Categories of medications at higher risk:

• ADHD medications: Brand-name stimulants and non-stimulants still under patent that aren't available as generics
• Anti-seizure medications: Patented brand-name drugs for common epilepsy types (not rare seizure disorders)
• Psychiatric medications: Brand-name antidepressants, anti-anxiety medications, and mood stabilizers without generic equivalents
• Specialty formulations: Extended-release versions, dissolving tablets, or liquid formulations of drugs that have generic immediate-release versions

Categories of medications that are likely protected by the exemptions:

• Orphan drugs: Treatments for rare genetic conditions, ultra-rare metabolic disorders, and diseases affecting small populations
• Cell and gene therapies: One-time treatments for genetic conditions (e.g., spinal muscular atrophy therapies)
• Plasma-derived therapies: Immunoglobulin treatments and clotting factors

Generic versions of any medication are exempt regardless of condition treated.

What Families Can Do Now

You have 120 to 180 days before the tariffs take effect. Use that time to get clear answers from your medical team and pharmacy.

Ask your pharmacist or prescriber:

• Is this medication patented or generic? If it's brand-name, is a generic version available?
• Is this drug designated as an orphan drug under the Orphan Drug Act?
• Where is this medication manufactured? Is it imported or made in the U.S.?
• If it's imported and not exempt, what therapeutic alternatives exist that are generic or manufactured domestically?

Document current pricing now. Note your current copay or out-of-pocket cost for each medication. If you're on a high-deductible plan or pay out of pocket, write down the cash price. This gives you a baseline to compare against after July 31 or September 29.

Review your formulary. If you have private insurance, check your plan's drug formulary to see which tier your medications are on. Contact your insurer to ask whether they anticipate formulary changes related to the tariffs.

Talk to your prescriber about alternatives before the tariff takes effect. If a medication is likely to be affected and therapeutic alternatives exist (generic versions, different drug classes, domestically manufactured options), discuss switching now rather than waiting until pricing changes or prior authorization requirements tighten.

Contact your insurance company or Medicaid office. Ask directly whether they've issued guidance on how the pharmaceutical tariffs will affect coverage, prior authorization, or formulary placement. Many states and insurers won't have answers yet, but your inquiry creates a record.

Where to Find More Information

The full text of the executive order is available on the White House website. The administration has not yet published a complete list of affected medications or manufacturers.

The FDA maintains a list of designated orphan drugs searchable by drug name or condition. If your child's medication appears on that list with an approved indication matching your child's diagnosis, it's exempt from the tariff.

For questions about Medicaid coverage, contact your state Medicaid office. For private insurance questions, contact your plan directly. Advocacy organizations including the Epilepsy Foundation, CHADD, and the Arc may issue guidance as more information becomes available.